Compare · HUM vs SERA
HUM vs SERA
Side-by-side comparison of Humana Inc. (HUM) and Sera Prognostics Inc. (SERA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUM and SERA operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $42.03B, about 468.7x SERA ($89.7M).
- SERA has been more active in the news (9 items in the past 4 weeks vs 4 for HUM).
- HUM has more recent analyst coverage (25 ratings vs 8 for SERA).
- Company
- Humana Inc.
- Sera Prognostics Inc.
- Price
- $355.91+1.64%
- $2.13-6.99%
- Market cap
- $42.03B
- $89.7M
- 1M return
- +43.90%
- -
- 1Y return
- +52.72%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 9
- Recent ratings
- 25
- 8
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Sera Prognostics Inc.
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest HUM
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach
- Humana upgraded by Deutsche Bank with a new price target
- Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Humana, CenterWell and USAA Unite with VFW for National Day of Service Supporting Veterans Experiencing Homelessness
- Humana Invests More Than $1 Million to Advance Health Outcomes Across Louisiana
- Chief Financial Officer Mellet Celeste gave a grant of 15,387 units of Humana Common, decreasing direct ownership by 28% to 39,637 units (SEC Form 4)
- Chief Information Officer Mehta Japan was granted 9,448 units of Humana Common, increasing direct ownership by 122% to 17,176 units (SEC Form 4)
- President, Enterprise Growth Dintenfass David was granted 11,273 units of Humana Common, increasing direct ownership by 80% to 25,407 units (SEC Form 4)
- President & CEO Rechtin James A. was granted 35,633 units of Humana Common (SEC Form 4)
Latest SERA
- SEC Form 144 filed by Sera Prognostics Inc.
- Sera Prognostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Elliott Jeffrey Thomas
- Craig Hallum initiated coverage on Sera Prognostics with a new price target
- General Counsel Jackson Benjamin was granted 5,000 shares, increasing direct ownership by 3% to 163,935 units (SEC Form 4)
- Chief Commercial Officer Anderson Dyaarl Lee Jr. was granted 3,168 shares, increasing direct ownership by 4% to 82,737 units (SEC Form 4)
- SEC Form DEFA14A filed by Sera Prognostics Inc.
- Sera Prognostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
- SEC Form 4 filed by Chief Data Officer Kearney Paul